Robert F. Kennedy Jr. is under increasing scrutiny as he prepares for a key Senate confirmation hearing for the role of HHS chief. Recent disclosures reveal complex financial arrangements, including substantial investments in gene-editing biotech firm CRISPR Therapeutics and significant profits from anti-vaccine activities, which he previously claimed were unpaid. Despite pledging to divest these interests if confirmed, questions surrounding his financial dealings, including profits derived from lawsuits against the agency he may lead, have raised concerns. With pressure mounting and no hearing scheduled yet, the path to confirmation appears fraught with obstacles.